Pharmacoeconomic evaluation of treatments for refractory schizophrenia: Clozapine-related studies

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 1, 1999, Pages 7-11

  Revicki, Dennis A ^a,b  

^a Center for Health Outcomes Research   (United States)

^b IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QUALITY OF LIFE; SCHIZOPHRENIA;

CLOZAPINE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0033044338     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Eisenberg J. Clinical economics: a guide to economic analysis of clinical practice. JAMA 1989;262:2879-2886
2. Buchanan R. Clozapine: efficacy and safety. Schizophr Bull 1995;21: 579-592
3. Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993:16:413-423
4. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1995;31:196-205
5. Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997;22:256-266
6. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995;31:57-65
7. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996;57(suppl 9):66-76
8. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996
9. Revicki DA, Luce BR, Weschler J, et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-854
10. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990;41:882-885
11. Frankenburg FR, Zanarini MC, Cole JO. et al. Hospitalization rates among clozapine-treatcd patients: a prospective cost-benefit analysis. Ann Clin Psychiatry 1992;4:247-250
12. Meltzer HY, Cola P, Way L, et al. Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638
13. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994;45:261-264
14. Revicki DA, Brown RE. Clozapine treatment and economic outcomes: an analysis of lifetime medical costs and health outcomes in treatment-resistant schizophrenia. Presented at "Clozaril: A National Dialogue." Virginia Department of Mental Health, Mental Retardation, and Substance Abuse Services; July 1992: Rosslyn, Va
15. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993;162:38-42
16. Oh P, Einarson TR, Iskedjian M, et al. Pharmacoeconomic Evaluation of Risperidone and Clozapine in Chronic and Treatment-Resistant Schizophrenia. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment; 1997
17. Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists, Int Clin Psychopharmacol 1996;11:101-108
18. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997;337:809-815
19. Essock SM, Hargraves WA, Covell NH, et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996;32:683-697
20. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398
21. Lehman AF. A quality of life interview for the chronically mentally ill. Eval Program Plann 1988;11:51-62
22. Daniel DG, Whitcomb SR. Treatment of the refractory schizophrenic patient. J Clin Psychiatry 1998;59(suppl 1):13-19